-
Ukraine Tension Prominent As Dow Suffers Triple Digit Loss; S&P 500 & NASDAQ Also Lower
Tuesday, August 5, 2014 - 4:46pm | 3092Read More...U.S. stocks declined and erased Monday's gains following reports that Russian troops were lining on the borders of Ukraine and preparing for an invasion, according to comments made by Poland's Foreign Minister. “Unfortunately, Russia has restored its combat readiness on the...
-
Market Wrap For June 20: Yet Again, Dow And S&P 500 Indices Hit New Highs
Friday, June 20, 2014 - 4:40pm | 2263Read More...U.S. stocks were slightly higher as the Dow and S&P 500 indices continue hitting new all-time highs following positive comments from the Fed's Chief Janet Yellen earlier this week. The Dow continues to flirt with the 17,000 mark and hit a historical intra-day high of 16,978.0 Friday...
-
Market Wrap For June 9: Markets Higher On St. Louis Fed Comments, Low Volume
Monday, June 9, 2014 - 4:42pm | 2188Read More...U.S. markets rose for the fourth straight session as investors positively digested comments coming from the St. Louis Fed. Jim Bullard, the St. Louis Fed chief said that inflation is low but moving back toward the two percent target. As such, Bullard argued that the Federal Reserve Open...
-
Market Wrap For March 14: Ukraine Tension Drag Markets Lower
Friday, March 14, 2014 - 5:17pm | 2348Read More...U.S. stocks declined as concerns escalated over Ukraine, two days before its citizens will vote in a referendum to split from Ukraine and become part of Russia. Russian President Vladimir Putin is gearing up to “invade eastern Ukraine” as a six hour talk between U.S. Secretary of State John...
-
BioMarin, Prestige Brands and Other Top Performing Health Care Stocks in November
Sunday, December 2, 2012 - 9:29pm | 617Read More...Here is a quick look at some of the top-performing health care sector stocks in the past month. These companies all have a market cap of more than $500 million, and their share prices are more than 20 percent higher than 30 days ago. BioMarin Pharmaceutical (NASDAQ: BMRN) in early November...
-
RIM, Green Mountain and Other Top Performing Nasdaq Stocks in November
Saturday, December 1, 2012 - 2:38pm | 597Read More...Here is a quick look at some of the top-performing Nasdaq stocks in the past month. These companies all have a market cap of more than $500 million and their share prices are more than 40 percent higher than 30 days ago. Green Mountain Coffee Roasters (NASDAQ: GMCR) shares jumped more than 32...
-
Best Biotech Stocks of 2011
Tuesday, December 27, 2011 - 11:39am | 830Read More...Here's a quick look at nine of the best-performing biotech stocks of the past year. Achillion Pharmaceuticals (NASDAQ: ACHN) is up almost 88% year to date and about 37% higher just in the past month. This Connecticut-based biopharmaceutical company has three drugs in clinical trials to treat...
-
Idenix and Spectrum Pharmaceuticals to Open Near 52-Week Highs
Tuesday, November 22, 2011 - 7:49am | 364Read More...While the markets were down yesterday, news that Gilead Sciences (NASDAQ: GILD) would acquire Pharmasset (NASDAQ: VRUS) pushed some biotech stocks higher. Idenix Pharmaceuticals (NASDAQ: IDIX) and Spectrum Pharmaceuticals (NASDAQ: SPPI) reached new multiyear highs of $8.05 and $13.00 per share,...
-
Bounce-Back Kings: 9 Stocks Up More Than 30% in the Past Month
Wednesday, September 14, 2011 - 8:23am | 841Read More...These nine stocks have bounced back from sell-offs in August, and their share prices are more than 30% higher than a month ago. Clearwire (NASDAQ: CLWR) shares are trading more than 60% higher than a month ago, despite pulling back more than 17% in the past week. Recent buyout rumors and the halt...
-
Brean Murray Initiates Idenix At Sell, $3 PT
Friday, June 17, 2011 - 7:38am | 27Read More...Brean Murray Carret & Company has initiated coverage on Idenix Pharmaceuticals (NASDAQ: IDIX) with a Sell rating and $3 price target.
-
Oppenheimer Comments On Idenix Pharmaceuticals 1Q11 Results
Thursday, April 28, 2011 - 8:19am | 147Read More...In a report published by Oppenheimer, Idenix Pharmaceuticals (NASDAQ: IDIX) IDIX reported 1Q11 results. Oppenheimer said that the company remains on track to initiate a 12-week ph.IIb study evaluating IDX184 with PEG/RBV in 2H11. “Based on ph.IIa results, we see a good probability '184 will...
-
Oppenheimer Maintains Perform on Idenix Pharmaceuticals (IDIX)
Tuesday, March 1, 2011 - 8:59am | 165Read More...Oppeneheimer is out with its report today on Idenix Pharmaceuticals (NASDAQ: IDIX), maintaining Perform. In a note to clients, Oppenheimer writes, "On 2/28, IDIX reported 4Q10 results. Since the recent lifting of the clinical hold on IDX184, the company remains on track to begin ph.IIb testing of...







